Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -466.34%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-207.87%
RETURN ON EQUITY (ROE) AVG 3Y
-106.09%
RETURN ON EQUITY (ROE) AVG 5Y
-81.10%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alector, Inc.
Market Cap
$220.94M
Return on Equity (ROE)
N/A
TTM Avg
-207.87%
3Y Avg
-106.09%
5Y Avg
-81.10%
Market Cap
$218.42M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$206.61M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.56M
Return on Equity (ROE)
-303.61%
TTM Avg
612.49%
3Y Avg
-57.80%
5Y Avg
-87.69%
Market Cap
$239.45M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$202.05M
Return on Equity (ROE)
-47.78%
TTM Avg
-64.50%
3Y Avg
-55.96%
5Y Avg
-125.52%
Market Cap
$244.25M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$245.65M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$248.21M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $220.94M | N/A | -207.87% | -106.09% | -81.10% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 39.66% | 4.24% | -15.88% | -20.06% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -303.61% | 612.49% | -57.80% | -87.69% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -25.20% | -25.82% | 5.12% | 5.12% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | -47.78% | -64.50% | -55.96% | -125.52% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | -118.58% | 62.37% | -376.78% | -340.60% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | 35.05% | 64.68% | -167.54% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -136.83% | -43.45% | -452.04% | -306.86% |
ROE
N/A
ROA
-58.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -466.34% |
| 2025-09-30 | -186.68% |
| 2025-06-30 | -161.98% |
| 2025-03-31 | -130.47% |
| 2024-12-31 | -93.89% |
| 2024-09-30 | -133.19% |
| 2024-06-30 | -106.71% |
| 2024-03-31 | -67.42% |
| 2023-12-31 | -97.19% |
| 2023-09-30 | -86.98% |
| 2023-06-30 | -72.88% |
| 2023-03-31 | -73.52% |
| 2022-12-31 | -62.17% |
| 2022-09-30 | -53.93% |
| 2022-06-30 | 12.57% |
| 2022-03-31 | -10.76% |
| 2021-12-31 | -12.08% |
| 2021-09-30 | -9.79% |
| 2021-06-30 | -115.00% |
| 2021-03-31 | -88.83% |
| 2020-12-31 | -71.11% |
| 2020-09-30 | -54.35% |
| 2020-06-30 | -41.54% |
| 2020-03-31 | -32.38% |
| 2019-12-31 | -54.11% |
| 2019-09-30 | -42.19% |
| 2019-06-30 | -30.85% |
| 2019-03-31 | -23.43% |
| 2018-06-30 | -50.36% |
| 2018-03-31 | -135.87% |
